Journal article

BRAF Mutations in Low-Grade Serous Ovarian Cancer and Response to BRAF Inhibition

Tania Moujaber, Dariush Etemadmoghadam, Catherine J Kennedy, Yoke-Eng Chiew, Rosemary L Balleine, Catherine Saunders, Gerard Wain, Bo Gao, Russell Hogg, Sivatharsny Srirangan, Casina Kan, Sian Fereday, Nadia Traficante, Ann-Marie Patch, John Pearson, Nicola Waddell, Sean M Grimmond, Alexander Dobrovic, David DL Bowtell, Paul R Harnett Show all



Purpose Low-grade serous ovarian carcinoma (LGSC) responds poorly to chemotherapy and is characterized by activating mutations in the Ras sarcoma-mitogen-activated protein kinase (RAS-MAPK) pathway, including oncogenic BRAF. However, response to BRAF inhibitors is tumor-type specific. Significant improvement in survival is seen in patients with BRAF-mutant melanoma, but other cancer types, such as colorectal cancers, are generally less sensitive. We examined the frequency and characteristics of BRAF-mutated LGSC and described the response to treatment with BRAF inhibitors. Patients and Methods Mutations were assessed in LGSC (N = 65) by using targeted, exome, and whole-genome sequencing. Pat..

View full abstract


Awarded by Cancer Council New South Wales Grant

Awarded by Cancer Institute New South Wales

Awarded by NHMRC

Awarded by US Army Medical Research and Materiel Command

Funding Acknowledgements

Supported by Cancer Council New South Wales Grant No. RG-15-23. The Westmead Gynaecological Oncology Biobank at Westmead is funded by Cancer Institute New South Wales Grants No. 12/RIG/1-17 and 15/RIG/1-16 and is a member bank of the Australasian Biospecimens Network-Oncology, funded by NHMRC Nos. ID310670 and ID628903. The Australian Ovarian Cancer Study was supported by the US Army Medical Research and Materiel Command under Grant No. DAMD17-01-1-0729, The Cancer Council Victoria, Queensland Cancer Fund, The Cancer Council New South Wales, The Cancer Council South Australia, The Cancer Foundation of Western Australia, The Cancer Council Tasmania, and the NHMRC Nos. ID400413 and ID400281. Also supported by S. Boldeman, the Agar family, Ovarian Cancer Australia, Ovarian Cancer Action (United Kingdom), and the Peter MacCallum Foundation. R.L.B., A.deF., and P.R.H. were funded by the Cancer Institute New South Wales through the Sydney-West Translational Cancer Research Centre. T.M. received funding as the recipient of an Early Career Research Scholarship from the Westmead Medical Research Foundation and The Jamel Alagha Ovarian Cancer Scholarship and is currently a recipient of a Research Training Program Scholarship from the University of Sydney and top-up scholarship from the Sydney-West Translational Cancer Research Centre.